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Monoclonal antibodies have proved useful in detecting antigenic variation at single determi-
nant sites on complex antigens, a fact which seems to have engendered a common mispercep-
tion that a monoclonal antibody is necessarily a "monospecific" agent. Yet there exists con-
siderable evidence that individual antibody molecules are multispecific in their binding
capabilities, and that the amount of functional and genetic redundancy in mammalian immune
systems may be quite large. The implications of this data for the future of monoclonal an-
tibodies are emphasized, along with a brief review of present progress toward human
monoclonal antibodies.
In a festschrift honoring Dr. Dorothy Horstmann, it seems particularly ap-
propriate to attempt a critical analysis of a popular subject. Those who have known
Dr. Horstmann respect her reverence for the study of basic scientific and
pathogenetic principles, rather than therapeutic adventurism based upon variant in-
terpretations of conventional wisdom. It is in this spirit that the present review is
undertaken.
Academic readers are not likely to have escaped the conventional wisdom about
monoclonal antibodies, which have been called "the smart bombs of biology" [1].
But few in medicine have a basis in training or experience for forming a critical ap-
preciation of the likely uses and limitations of these new agents. In this paper, I will
discuss relevant studies in biophysical chemistry and immunogenetics which suggest
that monoclonal antibodies, particularly in complex biomedical applications, may
often behave considerably less specifically than traditional heterogeneous antisera.
Then I will briefly review present progress toward obtaining human monoclonal an-
tibodies in vitro. Finally, based upon the reviewed evidence, I will suggest some cau-
tionary views toward their use in medicine.
A MONOCLONAL ANTIBODY MAY NOT BE A MONOSPECIFIC ANTIBODY
Precise knowledge of antibody structure, function, and molecular variability is
essential to an intelligent evaluation of the future of monoclonal antibodies. De-
tailed studies in the biophysical chemistry and the genetics of antibody molecules,
which have traditionally been conducted in separate quarters, are beginning to
sound similar refrains. Data from both types of analysis have tended to refute the
traditional notion of the antibody molecule as being, somehow, the most specific of
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all biologic ligands. This notion arose, in part, from the wonderfully exacting work
of Landsteiner [2], who demonstrated that antisera raised in animals to any of a
variety of inducing antigens exhibited, in general, exquisite specificity for the induc-
ing antigen, when tested in serologic reactions with that antigen and with related or
unrelated antigens. From Landsteiner's work, many inferred that individual an-
tibody molecules, which comprise the antisera, must themselves be exquisitely
specific in their binding activity. In light of the apparent ability to induce specific an-
tisera to an almost unlimited variety of antigens, a problematic implication of this
classical notion about antibody molecules was that their variety must be almost in-
finite.
The first investigator to publicly refute the classical notion of the specificity of an-
tibody molecules was Talmage, who in 1959 articulated the idea that individual an-
tibody molecules are likely to be multispecific in their binding functions [3].
Talmage argued that an antiserum, which comprises many different antibody
molecules, appears specific for the inducing antigen simply because each of the an-
tibodies in the antiserum has a significant binding affinity for determinants on the
inducing antigen, while other binding capabilities of each of the individual antibody
molecules are generally not seen because they are generally not held in common by
many of the molecules, so can not be detected above the threshold of activity
measurable in the usual serologic assays.
The idea that multispecific antibodies can, collectively, yield a pauci-specific an-
tiserum has been slow to assume a prominent place in everyday immunologic think-
ing, in part because actual data supporting it was not readily available, and the tradi-
tional concept, based on Landsteiner's work, was more firmly entrenched and
perhaps more attractive. However, experimental progress on this issue has been
made in the past 10 to 15 years, and because of the obvious implications for
monoclonal antibody work, the evidence offered for antibody multispecificity by
biophysical chemists and immunogeneticists will be briefly reviewed here.
In trying to show by straightforward combinatorial arithmetic that as few as 5,000
different antibody molecules could account for the essentially unlimited number of
binding "specificities" seen with traditional antisera, Talmage made the assumption,
based on little data at that time, that each distinct antibody molecule might be able
to combine with 0.01-1.0 percent of all possible antigens, "at some arbitrarily low
level of affinity" [3]. Several types of experimental data have shown this estimate to
be surprisingly accurate. Perhaps the best evidence comes from the study of purified
myeloma immunoglobulins. During the past 15 years, a number of myeloma pro-
teins from human and murine sources have been screened for binding activity to a
wide assortment of relatively simple compounds. Even with the relatively low
number of myeloma proteins tested (about 1,000-1,500), some binding functions
have been noted to occur repetitively, with the two most common types being bind-
ing to dinitrophenyl compounds and phosphorylcholine derivatives [4]. Further-
more, the extensive work of F.F. Richards and co-workers at Yale, has led Richards
to estimate that, for a given antibody, about one in 20 "compounds off the shelf"
will exhibit weak binding activity with the antibody combining site (association con-
stant Ko - 103 M-1), while about one in 140 to 200 compounds will bind with a
fairly high affinity to the antibody (Ko 2 105 M-l) [5,6,7; and F.F. Richards, per-
sonal communication]. These energies of interaction are in the range of those which
occur during the exercise of biologic function. The multispecificity of an antibody
combining site can occur because different antigens may bind at different, though
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sometimes spatially overlapping, points within the combining site [6]. Thus, in-
dividual antibody combining sites may exhibit significant affinity for a number of
different antigenic determinants. These determinants may be structurally related, or
completely unrelated. It has been pointed out that what matters is not the closeness
of fit, but rather the total interaction energy [7,8]. Richards has proposed the term
"linked specificities" to describe the phenomenon of a given antibody species react-
ing with two or more structurally dissimilar antigenic determinants [6].
In a brief review, it is not possible to cite all the biophysical evidence gathered to
date for multispecificity of antibody combining regions, or for the redundancy of
particular binding functions within the array ofspecificities exhibited by murine and
human antibodies. For more detailed analysis, the reader is referred to reviews by
Richards et al. [7] and by Inman [8]. At this point, however, it is appropriate to
review recent immunogenetic studies which demonstrate a considerable degree of
redundancy in the structure of the genes that encode antibody molecules.
One of the central facts to emerge from immunogenetics is that antibodies exhibit
a high degree of structural homology, both intramolecularly and intermolecularly.
The fornmer type of homology is seen as the three-dimensional structural similarity
of the various (four to five) 100 amino-acid domains of the antibody molecule to
each other. The latter is evident in the amino-acid sequence homology of correspond-
ing domains among different antibody molecules. Among the domains of the
antibody molecule, the greatest sequence variability is seen in the amino-terminal do-
main. This so-called variable-region domain, where antigen binding occurs, com-
prises the amino-terminal 110 amino-acids of the heavy chain (V1H) and the amino-
terminal 110 amino-acids of the light chain (VL). Extensive amino-acid sequence
data on VH and VL sequences has shown that different VH or VL sequences within the
same species infrequently differ by more than 30 percent ofthe amino-acid residues,
and the differences are often considerably less than that [9,101. Not surprisingly,
then, if one uses the nucleic acid sequence of one VL or VH region as a probe to iden-
tify similar sequences in murine or human germline DNA, the probe will generally
cross-hybridize to 4 to 20 genes in the germline DNA [11,12]. Limited data suggest
that these closely related, cross-hybridizing genes generally are located close together
in the genome [11]. These related genes may be referred to as VH or VL subsets. It
should be noted that their correspondence to the traditional V-region subgroups,
recognized on the basis ofamino-acid sequence data, is not yet clear. The number of
distinct (non cross-hybridizing) VH or VL subsets is presently unknown, but seems
likely to be relatively small; current estimates of the total number of VH or VL genes
vary widely but generally run to no more than one or two thousand genes of each
type, among which are scattered an indeterminate number of nonfunctional genes
called pseudogenes [1,12,13,14].
The amount of functional diversity observed within a set of related V-region se-
quences is not yet known. It appears, however, that closely homologous sequences
are often capable of qualitatively similar binding functions, as can be seen with an-
tibodies to phosphorylcholine [15]. If there were no somatic contribution to an-
tibody diversity-in other words, if all observed antibody VH and VL sequences were
found to be encoded in the germline-then the preceding data implies that the
number of qualitatively distinct antibody combining regions would be no greater
than the product of the numbers of functional VH and VL genes, and might more
closely resemble the product of the number of distinct VH and VL subsets, a much
smaller number. Recently, however, there has been increasing evidence for somatic
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mutation (the creation of altered antibody VH and VL sequences in developing
B-cells) [16,17]; the relative contribution of this mechanism to overall antibody
diversity is not yet clear, especially with regard to its impact for gross functional
diversity.
Why is there so much apparent redundancy in the murine and human genes en-
coding antibodies? The answer lies in the evolution of antibody genes. It appears
likely that all the domains of antibody molecules arose from a single 300-nucleotide
(100 amino-acid) sequence which emerged during the evolution of the first
vertebrates [18,19].
Thus, taken together, biophysical and genetic studies suggest that the structural
diversity of antibodies may be considerably less than was seemingly necessitated by
the classical notions of antibody specificity. And the functional diversity among in-
dividual molecules is presumably limited by the degree of structural diversity. It
should be noted, however, that the apparent functional diversity for a given
molecule or set of molecules will depend on the required energy ofinteraction. Low-
energy interactions are common and will give the appearance of little functional
distinction among antibodies, while higher energy interactions (Ko > 105 M-1) will
give the appearance of increasingly greater functional diversity among antibody
combining regions. The importance of these considerations for monoclonal an-
tibody work is evident, and can be reiterated as follows:
a. A monoclonal antibody may exhibit multiple different binding capabilities,
and a "serum" composed solely ofthis antibody will exhibit each ofthese bind-
ing specificities, as functions of their relative affinities in the test system. A
corollary is that these other specificities cannot be removed by absorption.
b. The use of monoclonal antibody preparations in increasingly complex an-
tigenic environments increases the likelihood that unwanted binding activities
will be observed, due to interactions with related (cross-reactive) or unrelated
("linked") determinants.
The likelihood of overcoming problems related to a. or b. above is related to the
ability to obtain many possible monoclonal antibodies with the desired binding
activity, in order to select the one whose unwanted binding activities are minimally
evident in the test system. In general, antibodies with high affinity for the desired
determinant are preferable, but the necessity of avoiding ligand activity with other
determinants may occasionally compel the choice of a lower-affinity antibody.
HUMAN MONOCLONAL ANTIBODIES
What, then, is the current prospect for obtaining human monoclonal antibodies
of such diversity as to be potentially useful? At present, it must be said that cell fu-
sion (hybridoma) technology has yielded limited success with human cell hybrids,
although such hybrids have been reported [20,21]. One of the main problems has
been the lack of suitable human myeloma carrier lines to which normal antigen
stimulated human B-cells could be fused [22,23]. Naturally occurring human
myelomas, unfortunately, are not readily cultivable into long-term cell lines,
although a few such lines have been derived. Other human B-cell lines exist, but
these are either EBV-transformed lymphoblastoid lines or human B-lymphoma lines
representing putatively different (generally earlier) stages of B-cell ontogeny than
the myeloma cell. The utility of both ofthese types of human B-cell lines for cell fu-
sion work is under current investigation, but it is possible that neither type will
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generally afford the close ontogenetic "match" apparently needed for successful cell
fusion work with normal B-cells [23].
The Epstein-Barr virus (EBV) itself immortalizes human B-cells. EBV-
transformed lines secreting specific human antibody to various antigens have been
derived [24]. Using high multiplicities of infection with transforming EBV, the
potential immortalization efficiency of this method appears to exceed that of
hybridoma technology [22,25,26]. Another advantage of the EBV method may be
that the cell lines tend to be diploid early in culture and are generally quite stable
[24,27], while hybridoma lines are aneuploid and tend to lose chromosomes, often
with untoward consequences for cell viability or immunoglobulin production
[22,28]. The chief disadvantage of the EBV methodology appears to be that the
EBV-transformed cell line secretes quantitatively less immunoglobulin (about 2-20
,ug/ml of cell culture) than hybridoma cell lines (about 10-100 ,^g/ml). Also, it is still
an open question as to whether EBV-mediated cell transformation will show a
preference for "activated" (antigen or mitogen stimulated) B-cells, as appears to be
the case for the cell fusion procedure [23].
Another potential method for obtaining human monoclonal antibodies would, of
course, be recombinant DNA technology, with translation of isolated im-
munoglobulin genes either in bacterial host cells or in a cell-free system. However,
while a totally artificial system may well be the way of the future, these prospects
seem remote at present, for several reasons. Antibodies are large four-chain
molecules of eukaryotic origin, whose synthesis and assembly in bacteria is currently
fraught with technical problems. Furthermore, antibodies undergo certain post-
translational modifications which might be difficult for bacterial cells to duplicate
(when necessary). Alternatively, systems based on a cell-free synthesis are relatively
inefficient at present, and do not reproduce large molecules well. Work on "ar-
tificial" antibody-like ligands is likely to progress, however, as molecular sub-
regions with distinct antigen-binding activity (or other biologic activities of interest)
are identified and characterized, allowing cell-free synthetic work with more limited
sequences.
CONCLUSIONS
In the present paper, I have reviewed the conceptual framework by which clini-
cians and biomedical research workers might anticipate some of the problematic
aspects of monoclonal antibodies, as they are likely to be observed in biomedical ap-
plications. Due to the multispecific nature of antibody combining regions, and the
homogeneity of monoclonal antibody preparations, unwanted binding activities are
likely to be observed when one attempts to probe increasingly complex biologic
systems with them. The adverse significance of these unwanted activities will, of
course, vary from one application to another. However, it should be noted that for
medical applications in which a monoclonal antibody is injected into a genetically
polymorphic species such as man, the occurrence of unwanted binding activities in
the individual recipient may be quite unpredictable. These unwanted binding ac-
tivities may become more evident when monoclonal antibodies are coupled with
various toxins. Additionally, the potential exists for novel derangements of the re-
cipient's immune system, arising from anti-allotype and anti-idiotype reactions which,
in genetically polymorphic recipients, may be difficult to anticipate and which are
likely to be more intense than those seen in reactions to heterogeneous antisera.
Thus, safety and efficacy assessments of monoclonal antibody products, for ap-
plications in outbred animal species, are likely to prove difficult.
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There is no question that monoclonal antibodies have provided a convenient
method by which separate determinants ofcomplex biological antigens may be iden-
tified and analyzed [291. The specificity and safety of a monoclonal antibody prod-
uct, however, needs rigorous evaluation in every application, especially those in-
volving medical therapeutics.
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